Perpetual Ltd Sells 80,864 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Perpetual Ltd reduced its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 2.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,551,813 shares of the biotechnology company's stock after selling 80,864 shares during the quarter. Perpetual Ltd owned about 1.50% of ADMA Biologics worth $70,468,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ADMA. Raymond James Financial Inc. bought a new position in ADMA Biologics during the 4th quarter worth approximately $19,076,000. JPMorgan Chase & Co. boosted its stake in shares of ADMA Biologics by 272.5% in the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after purchasing an additional 561,310 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of ADMA Biologics by 52.8% during the fourth quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock worth $1,886,000 after buying an additional 38,002 shares during the period. Sei Investments Co. raised its stake in ADMA Biologics by 147.2% during the fourth quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock worth $9,043,000 after buying an additional 314,013 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in ADMA Biologics by 6.6% in the fourth quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company's stock valued at $7,862,000 after buying an additional 28,500 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Raymond James Financial lifted their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th.

ADMA Biologics Stock Up 4.5%

Shares of NASDAQ ADMA opened at $18.40 on Friday. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22. The firm has a market cap of $4.39 billion, a PE ratio of 21.65 and a beta of 0.47. The company's fifty day simple moving average is $20.69 and its 200 day simple moving average is $18.76. ADMA Biologics Inc has a 12-month low of $10.21 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. During the same period last year, the company earned $0.08 EPS. ADMA Biologics's revenue for the quarter was up 40.2% compared to the same quarter last year. As a group, sell-side analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 7,779 shares of the firm's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total value of $158,069.28. Following the transaction, the director now directly owns 114,830 shares of the company's stock, valued at approximately $2,333,345.60. This trade represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steve Elms sold 92,941 shares of the business's stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $21.69, for a total transaction of $2,015,890.29. Following the sale, the director now directly owns 2,031,730 shares of the company's stock, valued at approximately $44,068,223.70. The trade was a 4.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 464,621 shares of company stock valued at $9,644,269. Company insiders own 3.50% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.